Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ligand Pharmaceuticals (LGND) Other Working Capital Changes: 2009-2024

Historic Other Working Capital Changes for Ligand Pharmaceuticals (LGND) over the last 16 years, with Dec 2024 value amounting to $7.7 million.

  • Ligand Pharmaceuticals' Other Working Capital Changes rose 98.15% to -$148,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $15.0 million, marking a year-over-year increase of 77.09%. This contributed to the annual value of $7.7 million for FY2024, which is 21.71% down from last year.
  • According to the latest figures from FY2024, Ligand Pharmaceuticals' Other Working Capital Changes is $7.7 million, which was down 21.71% from $9.9 million recorded in FY2023.
  • Ligand Pharmaceuticals' Other Working Capital Changes' 5-year high stood at $29.2 million during FY2020, with a 5-year trough of -$17.9 million in FY2021.
  • Moreover, its 3-year median value for Other Working Capital Changes was $7.7 million (2024), whereas its average is $3.7 million.
  • In the last 5 years, Ligand Pharmaceuticals' Other Working Capital Changes surged by 935.79% in 2020 and then plummeted by 161.12% in 2021.
  • Ligand Pharmaceuticals' Other Working Capital Changes (Yearly) stood at $29.2 million in 2020, then slumped by 161.12% to -$17.9 million in 2021, then skyrocketed by 64.51% to -$6.3 million in 2022, then surged by 255.55% to $9.9 million in 2023, then dropped by 21.71% to $7.7 million in 2024.